Detalhe da pesquisa
1.
Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas.
Mod Pathol
; 37(2): 100404, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104891
2.
Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
Cancer
; 129(24): 3884-3893, 2023 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37565840
3.
The Genomic Landscape of Vulvar Squamous Cell Carcinoma.
Int J Gynecol Pathol
; 42(5): 515-522, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37131274
4.
Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions.
Cancer Treat Res
; 184: 41-51, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36449186
5.
Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors.
Int J Cancer
; 149(7): 1455-1462, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34124786
6.
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
Oncologist
; 26(8): e1418-e1426, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33586299
7.
End of an era for erythropoiesis-stimulating agents in oncology.
Int J Cancer
; 146(10): 2829-2835, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037527
8.
Rituximab biosimilars in hematologic malignancies: the need for a real-world approach.
Future Oncol
; 16(26): 2017-2027, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32598173
9.
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Cancer
; 125(11): 1830-1836, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30707764
10.
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
Oncologist
; 24(4): 537-548, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842244
11.
Strengthening the Medical Error "Meme Pool".
J Gen Intern Med
; 34(10): 2264-2267, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292902
12.
Barriers to Oncology Biosimilars Uptake in the United States.
Oncologist
; 23(11): 1261-1265, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30049886
13.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Blood
; 128(18): 2199-2205, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27601462
14.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica
; 103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880613
15.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol
; 93(11): 1394-1401, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30132965
16.
Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research.
Future Oncol
; 14(27): 2841-2848, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29848070
17.
Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
Br J Haematol
; 177(1): 72-79, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211579
18.
Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
BMC Cancer
; 17(1): 198, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28302090
19.
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
Hematol Oncol
; 35(4): 528-535, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28066928
20.
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.
Am J Hematol
; 92(11): 1156-1162, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28719025